Ribosome Newsletter: Navigating the Convergence of Proteomics, AI, Synthetic Biology, and Translational Medicine
Welcome to this week's edition of the Ribosome. In this issue, we delve into groundbreaking research uncovering biomarkers in kidney injury, Alzheimer's, liver cancer, and colorectal cancer, showcasing the pivotal role of proteomics in enhancing our understanding and treatment of these diseases. Additionally, our industry updates highlight Pfizer's strategic acquisition of Seagen and Bristol Myers Squibb's collaboration with SystImmune, among other key developments in the pharmaceutical realm.
Biomarker Discovery
This study utilized single-nucleus RNA sequencing of kidney biopsies and plasma proteomics to explore acute kidney injury (AKI). It revealed that maladaptive repair processes in the kidney's proximal tubules, marked by cell dedifferentiation and increased inflammatory and fibrotic pathways, play a crucial role in AKI. Additionally, the research identified specific plasma proteins linked to this maladaptive response, offering potential biomarkers for early detection and new targets for therapy. These findings were validated in both human patients and mouse models, enhancing understanding of AKI and its progression to chronic kidney disease.
This study used mass spectrometry to analyze cerebrospinal fluid from a large clinical cohort, discovering that increased levels of glycolytic enzymes, particularly pyruvate kinase and aldolase A, are associated with Alzheimer’s disease. This finding suggests a link between disrupted glucose metabolism and Alzheimer's, potentially providing biomarkers for the disease.
This study conducted an extensive multi-omics analysis (genomic, transcriptomic, proteomic, and phosphoproteomic) of hepatocellular carcinoma (HCC), identifying three unique HCC subtypes with different clinical outcomes. It proposed a simplified nine-protein panel for clinical differentiation of these subtypes. The research uncovered notable distinctions among the subtypes in genetic alterations, microenvironment changes, and kinase-substrate networks, which correlated with varied responses to the HCC treatment sorafenib. A machine-learning model was also developed to predict patient-specific responses to sorafenib, underlining the role of proteomic and phosphoproteomic insights in tailoring precision medicine approaches for HCC.
In this study, scientists analyzed 254 colorectal cancer tissue samples, revealing four proteomic subtypes that differed in response to chemotherapy, chemoradiation, and targeted treatments like cetuximab. They identified HSF1 as a key protein increasing resistance to radiation, while the overexpression of HDAC6, regulated by NFYC, was linked to cetuximab resistance. This research offers a pathway for more personalized and effective treatment strategies for colorectal cancer patients.
Industry Updates
Pfizer Inc. finalizes its $43 billion acquisition of Seagen Inc., a strategic move that substantially boosts its oncology portfolio and establishes Pfizer as a key player in the field. The deal, which incorporates Seagen's advanced Antibody-Drug Conjugate (ADC) technology and includes four primary medicines - ADCETRIS, PADCEV, TIVDAK, and TUKYSA - enhances Pfizer's therapeutic capabilities. To mitigate U.S. Federal Trade Commission regulatory concerns, Pfizer will donate all U.S. Bavencio royalties to the American Association for Cancer Research.
领英推荐
Bristol Myers Squibb (BMS) and SystImmune have formed a partnership for the development of BL-B01D1, a bi-specific antibody-drug conjugate targeting EGFR and HER3 proteins in solid tumors. Under the deal, BMS will make an $800 million upfront payment, up to $500 million in near-term payments, and could pay up to $7.1 billion in milestones. BMS secures co-development and co-commercialization rights in the U.S., while SystImmune maintains exclusive rights in Mainland China. This agreement augments BMS's oncology portfolio, aligning with its recent strategic moves in cancer therapy development.
Evotec SE teams up with Charité – Universit?tsmedizin Berlin, focusing on expanding its molecular database in autoimmune diseases, notably ANCA-associated vasculitis (AAV). This partnership, centered on creating an extensive PanOmics database incorporating genomics and other advanced data from patient biosamples, aims to foster precision medicine therapies using Evotec's E.MPD platform and machine learning. While Charité benefits from academic access to the data, Evotec retains exclusive commercial development rights. Financial terms remain undisclosed.
The proteomics market is poised for a robust expansion, set to soar to USD 79.5 billion by 2031 from USD 28.2 billion in 2022, at a CAGR of 12.2%. This growth trajectory is fueled by breakthroughs in personalized medicine, heightened R&D investments in biopharmaceuticals, and supportive governmental policies. The industry's shift towards systemic biology and the burgeoning establishment of proteomic divisions in pharma companies further underscore this upward trend.
The global microfluidics market, valued at USD 20.7 billion in 2021, is projected to reach USD 58.8 billion by 2026, growing at a CAGR of 23.2%. This growth is driven by the increasing demand for point-of-care testing and technological advancements in microfluidic-based devices and components across various sectors including in vitro diagnostics, research, and pharmaceutical manufacturing.
The global protein sequencing market is on track to double from $1.9 billion to $4.0 billion by 2030, growing at an 11.2% CAGR. This growth is fueled by rising demands in personalized medicine and proteomics research. Key areas of application include drug discovery, toxicology, and vaccine development, with market trends leaning towards Next-Generation Sequencing technologies and bioinformatics analysis.
The worldwide market for protein assays, a pivotal tool in drug development and disease diagnosis, is forecasted to hit a value of $4.4 billion by 2032, expanding at a 6.5% CAGR. North America currently dominates this arena, but Asia-Pacific is poised for swift growth. Market leaders are strategically launching new products and forging partnerships to broaden their footprint. While grappling with challenges such as elevated costs and the necessity for uniform protocols, the sector stands to benefit from advancements in personalized medicine and robust research and development activities.
The global market for antibody testing, spurred by an uptick in chronic diseases including cancer and autoimmune disorders, is on track to surge to $18.9 billion by 2034, from $9.2 billion in 2024. Growing at a 7.5% CAGR, this expansion is fueled by technological leaps in disease biomarkers and the increasing uptake of health insurance programs. The United States is set to lead the charge, backed by hefty investments in R&D and product innovation.
Ribosome Ventures: [email protected]
#proteomics #biomarkers #ai #decadeofproteomics #translationalmedicine #syntheticbiology
"It's amazing to see someone so dedicated to exploring the mysteries of life and striving for eternal knowledge. As Steve Jobs once said, 'Your time is limited, don’t waste it living someone else’s life.' ?? Keep pushing boundaries and making your unique mark on the world. ??"